RT Journal Article
SR Electronic
T1 A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6243
OP 6248
VO 36
IS 12
A1 HANCOCK, BRYAN M.
A1 MCGUIRE, KATHLEEN L.
A1 TSUJI, SHINGO
A1 REIL, KATHERINE
A1 HERNANDEZ, VERONICA
A1 GIACALONE, MATTHEW J.
A1 GODBEY, W. T.
YR 2016
UL http://ar.iiarjournals.org/content/36/12/6243.abstract
AB Background/Aim: VAX014 minicells (VAX014) have been previously characterized as an integrin-specific oncolytic biotherapeutic agent. The present study was designed to evaluate the potential of VAX014 as an immediate post-operative intravesical adjuvant therapy in the treatment of non-muscle invasive bladder cancer (NMIBC). Materials and Methods: The ability of VAX014 to kill a panel of dissociated urothelial carcinoma cell lines was tested in vitro. In vivo experiments were conducted using a single intravesical dose of VAX014 in the anti-implantation variation of the MB49 syngeneic orthotopic bladder cancer model with tumor implantation and overall survival rates serving as study endpoints. Results: VAX014 rapidly killed dissociated urothelial carcinoma cells, while single dose in vivo pharmacology studies demonstrated the dose-dependent ability of VAX014 to prevent tumor implantation and development, ultimately resulting in a significant survival advantage compared to controls. Conclusion: These results suggest that VAX014 holds potential as an immediate post-operative adjuvant therapy in NMIBC.